Cancer vaccines based on mRNA are extensively studied. The fragile nature of mRNA has instigated research into carriers that can protect it from ribonucleases and as such enable its systemic use. However. copyright-mediated delivery of mRNA has been linked to production of type I interferon (IFN) that was reported to compromise the effectiveness of mRNA vaccines. https://www.roneverhart.com/2003-2005-HONDA-ACCORD-2-4L-4-Cylinder-Engine-Upper-Intake-Manifold-OEM/